Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VERA Vera Therapeutics, Inc.

Trading 03-05 13:30:46 EST

38.50

-1.15

-2.90%

High39.80	Low38.30	Vol407.72K
Open38.93	D1 Closing39.65	Amplitude3.78%
Mkt Cap2.75B	Tradable Cap1.93B	Total Shares71.36M
T/O15.91M	T/O Rate0.81%	Tradable Shares50.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VERA","market":"US","secType":"STK","nameCN":"Vera Therapeutics, Inc.","latestPrice":38.5,"timestamp":1772735444774,"preClose":39.65,"halted":0,"volume":407718,"delay":0,"changeRate":-0.029003783102143722,"floatShares":50198200,"shares":71355667,"eps":-4.664443,"marketStatus":"Trading","change":-1.15,"latestTime":"03-05 13:30:46 EST","open":38.93,"high":39.8,"low":38.3,"amount":15914450.985948,"amplitude":0.037831,"askPrice":38.66,"askSize":178,"bidPrice":38.41,"bidSize":110,"shortable":3,"etf":0,"ttmEps":-4.664443,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772744400000},"marketStatusCode":2,"adr":0,"listingDate":1620964800000,"exchange":"NASDAQ","adjPreClose":39.65,"preHourTrading":{"tag":"盘前","latestPrice":38.93,"preClose":39.65,"latestTime":"09:29 EST","volume":73,"amount":2886.37036,"timestamp":1772720999968,"change":-0.72,"changeRate":-0.018159,"amplitude":0.025473},"postHourTrading":{"tag":"盘后","latestPrice":39.65,"preClose":39.65,"latestTime":"19:06 EST","volume":94834,"amount":3760126.35,"timestamp":1772669217833,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.534561,"impliedVol":1.1805,"impliedVolPercentile":0.745},"requestUrl":"/m/hq/s/VERA","defaultTab":"news","newsList":[{"id":"2617523074","title":"Vera Therapeutics appoints Hite to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2617523074","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617523074?lang=en_us&edition=fundamental","pubTime":"2026-03-05 22:16","pubTimestamp":1772720191,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (VERA) announced the appointment of Christopher Hite to Vera Therapeutics’ Board of Directors. Published first on TheFly – the ul...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-appoints-hite-to-board-of-directors-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-appoints-hite-to-board-of-directors-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","VERA","BK4539","BK4588","LU2324357040.USD"],"gpt_icon":0},{"id":"2617523822","title":"Vera Therapeutics Appoints Christopher Hite to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2617523822","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617523822?lang=en_us&edition=fundamental","pubTime":"2026-03-05 22:00","pubTimestamp":1772719200,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., March  05, 2026  (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/05/3250276/0/en/Vera-Therapeutics-Appoints-Christopher-Hite-to-Board-of-Directors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4588","LU2324357040.USD","BK4539","VERA"],"gpt_icon":0},{"id":"2616332316","title":"Vera Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2616332316","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616332316?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:53","pubTimestamp":1772455980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VERA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 07:53 ET (12:53 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA"],"gpt_icon":0},{"id":"2616770339","title":"Bank of America Securities Reaffirms Their Buy Rating on Vera Therapeutics (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616770339","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616770339?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:57","pubTimestamp":1772452658,"startTime":"0","endTime":"0","summary":"In a report released today, Dina Ramadane from Bank of America Securities reiterated a Buy rating on Vera Therapeutics, with a price target of $66....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-reaffirms-their-buy-rating-on-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-reaffirms-their-buy-rating-on-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA","BAC"],"gpt_icon":0},{"id":"2616335065","title":"Vera Therapeutics price target raised to $110 from $90 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2616335065","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616335065?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:11","pubTimestamp":1772449901,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Vera Therapeutics (VERA) to $110 from $90 and keeps a Buy rating on the shares. The firm updated ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-price-target-raised-to-110-from-90-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-price-target-raised-to-110-from-90-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA"],"gpt_icon":0},{"id":"2614816513","title":"Positive Phase 3 IgA Data and FDA Priority Review Could Be A Game Changer For Vera Therapeutics (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614816513","media":"Simply Wall St.","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614816513?lang=en_us&edition=fundamental","pubTime":"2026-02-28 17:30","pubTimestamp":1772271010,"startTime":"0","endTime":"0","summary":"Vera Therapeutics reported full-year 2025 results showing a net loss of US$299.62 million, while advancing atacicept with positive Phase 3 IgA nephropathy data and securing FDA priority review with a July 7, 2026 PDUFA date.\nAlongside filing a US$191.89 million Class A common stock shelf registration for an ESOP-related offering, the company highlighted that its cash, equivalents, marketable securities and debt facility availability are expected to fund operations through potential atacicept...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/positive-phase-3-iga-data-and-fda-priority-review-could-be-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/positive-phase-3-iga-data-and-fda-priority-review-could-be-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","VERA","BK4585","BK4539","BK4588"],"gpt_icon":0},{"id":"2614938448","title":"Vera Therapeutics: Strong Atacicept Phase 3 Data and Favorable Regulatory, Commercial Setup Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2614938448","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614938448?lang=en_us&edition=fundamental","pubTime":"2026-02-28 06:45","pubTimestamp":1772232326,"startTime":"0","endTime":"0","summary":"Ritu Baral, an analyst from TD Cowen, maintained the Buy rating on Vera Therapeutics. The associated price target remains the same with $73.00. Rit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/vera-therapeutics-strong-atacicept-phase-3-data-and-favorable-regulatory-commercial-setup-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/vera-therapeutics-strong-atacicept-phase-3-data-and-favorable-regulatory-commercial-setup-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA"],"gpt_icon":0},{"id":"2614856514","title":"Wedbush Raises Price Target on Vera Therapeutics to $35 From $33, Keeps Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2614856514","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614856514?lang=en_us&edition=fundamental","pubTime":"2026-02-27 21:14","pubTimestamp":1772198066,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (VERA) has an average rating of buy and mean price target of $77.23, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VERA"],"gpt_icon":0},{"id":"2614537448","title":"Guggenheim Keeps Their Buy Rating on Vera Therapeutics (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614537448","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614537448?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:39","pubTimestamp":1772195955,"startTime":"0","endTime":"0","summary":"In a report released yesterday, from Guggenheim reiterated a Buy rating on Vera Therapeutics, with a price target of $56.00. The company’s shares c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA"],"gpt_icon":0},{"id":"2614775320","title":"Vera Therapeutics Q4 EPS $(1.39) Misses $(1.31) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2614775320","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614775320?lang=en_us&edition=fundamental","pubTime":"2026-02-27 06:49","pubTimestamp":1772146192,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(1.31) by 6.19 percent. This is a 93.06 percent decrease over losses of $(0.72) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50916305/vera-therapeutics-q4-eps-1-39-misses-1-31-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vera Therapeutics Q4 EPS $(1.39) Misses $(1.31) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA"],"gpt_icon":0},{"id":"2614007459","title":"Vera Therapeutics: Buy Rating Backed by Strong Atacicept Data, Robust Cash Runway, and Large IgAN Market Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2614007459","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614007459?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:56","pubTimestamp":1772142961,"startTime":"0","endTime":"0","summary":"Vera Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rami Katkhuda from LifeSci Capital assigned...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/vera-therapeutics-buy-rating-backed-by-strong-atacicept-data-robust-cash-runway-and-large-igan-market-opportunity-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/vera-therapeutics-buy-rating-backed-by-strong-atacicept-data-robust-cash-runway-and-large-igan-market-opportunity-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA"],"gpt_icon":0},{"id":"2614007627","title":"Vera Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2614007627","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614007627?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:13","pubTimestamp":1772140421,"startTime":"0","endTime":"0","summary":"Vera Therapeutics Inc reports results for the quarter ended September 30 - Earnings SummaryVera Therapeutics Inc VERA.OQ reported a quarterly adjusted loss of $1.39 per share for the quarter ended Sep","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL8N3ZM38D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4539","BK4588","VERA"],"gpt_icon":0},{"id":"2614041882","title":"Vera Therapeutics' 2025 net loss wider than expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2614041882","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614041882?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:40","pubTimestamp":1772109659,"startTime":"0","endTime":"0","summary":"Vera Therapeutics' 2025 net loss wider than expectationsOverviewBiotechnology firm's 2025 net loss of $299.6 mln missed analyst expectationsLoss per share for 2025 missed analyst estimatesCompany prep","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL1N3ZM0NP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VERA","BK4588","BK4585","BK4539"],"gpt_icon":0},{"id":"2614974049","title":"Vera reports FY 2025 net loss of USD 299.6 million, R&D spend USD 215.3 million up 70.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614974049","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614974049?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:32","pubTimestamp":1772109120,"startTime":"0","endTime":"0","summary":"Vera Therapeutics reported a FY 2025 net loss of USD 299.6 million and a net loss per diluted share of USD 4.66. Net cash used in operating activities was USD 241.1 million in FY 2025. The company ended FY 2025 with USD 714.6 million in cash, cash equivalents, and marketable securities. During the period, Vera said the FDA granted priority review to its Biologics License Application for atacicept in IgA nephropathy, with a PDUFA target action date of July 7, 2026, and the company expects a potential U.S. commercial launch in mid-2026 if approved. Vera also highlighted positive Phase 3 ORIGIN 3 data presented at ASN Kidney Week 2025 and published in the New England Journal of Medicine, and noted combined potential gross proceeds of USD 800.0 million from 2025 equity financing and a debt agreement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL8bP42W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4139","LU2095319765.USD","LU0314104364.USD","BK4588","BK4539","IE00BKPKM429.USD","SG9999014039.USD","VERA","NDAQ","BK4585","SG9999014005.SGD","LU2210150020.SGD","LU2210149790.SGD","SG9999014013.SGD","BK4112","SG9999014021.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2614495220","title":"BRIEF-Vera Therapeutics FY EPS USD -4.66 Vs. IBES Estimate USD -4.55","url":"https://stock-news.laohu8.com/highlight/detail?id=2614495220","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614495220?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:30","pubTimestamp":1772109047,"startTime":"0","endTime":"0","summary":"Feb 26  - Vera Therapeutics FY operating expenses USD 315.473 million.FY net income USD -299.615 million vs. IBES estimate USD -292.5 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX498EEA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4585","BK4588","BK4139","VERA"],"gpt_icon":0},{"id":"2614496960","title":"Vera Therapeutics FY Operating Expenses USD 315.473 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614496960","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614496960?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:30","pubTimestamp":1772109002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX498EEA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VERA","BK4585","BK4539","BK4139","BK4588"],"gpt_icon":0},{"id":"2614049962","title":"Vera Therapeutics FY EPS USD -4.66 VS. Ibes Estimate USD -4.55","url":"https://stock-news.laohu8.com/highlight/detail?id=2614049962","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614049962?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:30","pubTimestamp":1772109002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX498EEA:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4585","BK4588","BK4139","VERA"],"gpt_icon":0},{"id":"2614049955","title":"Vera Therapeutics Inc - Atacicept Commercial Launch Expected Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2614049955","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614049955?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:30","pubTimestamp":1772109002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX498EEA:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VERA","BK4539","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2614404915","title":"Press Release: Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2614404915","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614404915?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:30","pubTimestamp":1772109000,"startTime":"0","endTime":"0","summary":"-- Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy.  presented at American Society of Nephrology  Kidney Week and. -- U.S. Food and Drug Administration  granted priority review to. Biologics License Application  for atacicept with Prescription Drug. User Fee Act  date of July 7, 2026; potential commercial launch of. -- Strong balance sheet bolstered by equity and debt financings in 2025. expected to be sufficient to fund company beyond atacicept approval and. \"In 2025, Vera Therapeutics delivered on several key milestones as we advanced atacicept toward potential FDA approval and commercialization,\" said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. \"The BLA has been granted priority review and we expect to be commercially prepared to successfully launch atacicept in IgAN in mid-2026 if approved. Our commercial team brings decades of experience launching innovative therapies and is eager to bring this potentially disease-modifying therapy to pa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0004445015.USD","BK4581","BK4504","BK4139","LU1732800096.USD","BK4534","IE00B7KXQ091.USD","LU1244550577.SGD","BK4566","LU1430594728.SGD","TACI","LU2347655156.SGD","IE00BFSS8Q28.SGD","LU1035773651.USD","LU0726765562.USD","BK4610","LU1718418525.SGD","BK4539","BK4550","IE00BJJMRX11.SGD","LU0795875086.SGD","IE00BJTD4V19.USD","IE00BJJMRY28.SGD","IE00BJTD4N35.SGD","LU0868494708.USD","LU1244550494.USD","LU1732799900.SGD","LU0795875169.SGD","LU2347655073.USD","LU0942090050.USD","LU0868494617.USD","LU1074936037.SGD","LU2279689827.SGD","LU0417517546.SGD","LU1069347547.HKD","MCD","LU1585245621.USD","LU0256863811.USD","LU1244550221.USD","BK4585","VERA","BK4209","LU0912757837.SGD","FSGS","LU2133065610.SGD","IE00BFSS7M15.SGD","BK4588"],"gpt_icon":0},{"id":"2613471145","title":"Vera Therapeutics to Present at TD Cowen Annual Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2613471145","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613471145?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:03","pubTimestamp":1771938189,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL5f5BX2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4539","VERA","BK4588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.veratx.com","stockEarnings":[{"period":"1week","weight":-0.0487},{"period":"1month","weight":-0.1243},{"period":"3month","weight":-0.0695},{"period":"6month","weight":0.6391},{"period":"1year","weight":0.3864},{"period":"ytd","weight":-0.217}],"compareEarnings":[{"period":"1week","weight":-0.0116},{"period":"1month","weight":-0.0148},{"period":"3month","weight":0.0011},{"period":"6month","weight":0.0585},{"period":"1year","weight":0.1877},{"period":"ytd","weight":0.0047}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":0.057587},{"month":2,"riseRate":0.4,"avgChangeRate":0.015839},{"month":3,"riseRate":0.4,"avgChangeRate":-0.050608},{"month":4,"riseRate":0,"avgChangeRate":-0.100599},{"month":5,"riseRate":0.25,"avgChangeRate":-0.061241},{"month":6,"riseRate":0.4,"avgChangeRate":0.164504},{"month":7,"riseRate":0.8,"avgChangeRate":0.137629},{"month":8,"riseRate":0.6,"avgChangeRate":0.019112},{"month":9,"riseRate":0.6,"avgChangeRate":0.088867},{"month":10,"riseRate":0.2,"avgChangeRate":-0.071412},{"month":11,"riseRate":0.8,"avgChangeRate":0.292871},{"month":12,"riseRate":0.6,"avgChangeRate":0.07812}],"exchange":"NASDAQ","name":"Vera Therapeutics, Inc.","nameEN":"Vera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vera Therapeutics, Inc.(VERA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vera Therapeutics, Inc.,VERA,Vera Therapeutics, Inc.股票,Vera Therapeutics, Inc.股票老虎,Vera Therapeutics, Inc.股票老虎国际,Vera Therapeutics, Inc.行情,Vera Therapeutics, Inc.股票行情,Vera Therapeutics, Inc.股价,Vera Therapeutics, Inc.股市,Vera Therapeutics, Inc.股票价格,Vera Therapeutics, Inc.股票交易,Vera Therapeutics, Inc.股票购买,Vera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vera Therapeutics, Inc.(VERA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}